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Introduction: Pneumonectomy (PN) after induction chemotherapy
(CT) for non-small cell lung cancer is controversial because high-
mortality rates are still reported.
Methods: This multicenter retrospective study included all patients
treated by induction CT then PN between January 1993 and April
2006 in four General and Thoracic Surgery Departments. Postoper-
ative mortality and morbidity and long-term outcomes were studied.
Results: The study considered 228 patients. Doublets with cisplatin
and vinorelbine or gemcitabine were used in 66% of cases. pTNM
stages (World Health Organization, 1997) were 0 (2%), I (16%), II
(25%), IIIA (29%), IIIB (16%), and IV (12%). The postoperative
morbidity rate was 37% (84 of 228 patients). The independent risk
factors identified for postoperative morbidity were chronic obstruc-
tive pulmonary disease, more than four cycles of induction CT or an
association of cisplatin, and an old cytotoxic molecule, extended PN,
and extended anesthesia time. Postoperative mortality rates were
5.3% at 30 days (12 of 228 patients) and 9.2% at 90 days (21 of 228
patients). The independent risk factors identified for operative mor-
tality were chronic obstructive pulmonary disease, manual suture of
the stump, and pTNM stage higher than IIIA. The 90-day mortality
rates were 10.3% (12 of 117) for right PN and 8.2% (9 of 111) for
left PN (p  0.65). The overall survival (OS) rates were 68% at 1
year, 39% at 3 years, and 32% at 5 years.
Conclusions: Induction CT was not found to compromise short- or
long-term outcomes after PN in non-small cell lung cancer. The
right or left PN performed by experienced surgeons after induction
CT seems to be a reasonable procedure in case of tumor local
extension.
Key Words: Non-small cell lung cancer, Induction chemotherapy,
Surgery, Pneumonectomy, Chronic obstructive pulmonary disease.
(J Thorac Oncol. 2009;4: 1496–1503)
Despite several phase III studies1,2 or meta-analyses,3induction chemotherapy (CT) failed to show clear ben-
efits in the treatment of resectable non-small cell lung cancer
(NSCLC).4 Nevertheless, induction CT was, and is still,
widely used, especially in stage IIIA. Indeed, in stage II,
adjuvant CT became recently the new standard recommended
by American and French guidelines.5,6
Induction CT is generally believed to increase postop-
erative morbimortality, especially after pneumonectomy
(PN). Martin et al.7 and Doddoli et al.8 reported unacceptable
postoperative mortality rates after induction CT and right PN:
24% and 26%, respectively. The Radiation Therapy Oncology
Group 9309 trial reported a 25% mortality rate after concurrent
induction CT and radiotherapy (RT) and PN.9 In the recent
American College of Chest Physicians guidelines, full-dose RT
is now preferred to PN in stage IIIA after induction RT-CT.10
PN, especially right PN, after induction CT became the most
controversial combination in the treatment of NSCLC and is
now contraindicated by many multidisciplinary teams.
However, this new recommendation is based on mono-
center retrospective studies that reflect the experience of only
one team or on a limited subgroup of randomized trials that
included small numbers of patients. Besides, other publica-
tions reported more reasonable postoperative mortality rates,
2 to 12%.11–14
We conducted a multicenter retrospective study to as-
sess the postoperative morbidity and the 90-day mortality,
together with their prognostic factors, and to evaluate the
long-term outcomes, in terms of survival and lung function,
after induction CT and PN for NSCLC. The asset was the
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inclusion of a large number of patients treated by different
oncologic and surgical teams, each with its own procedures
and practices.
PATIENTS AND METHODS
Patients
All consecutive patients attending four General and
Thoracic Surgery Departments in Lyon and Saint-Etienne,
France, between January 1, 1993, and April 30, 2006, were
included if they had a histologically or cytologically proven
NSCLC and were treated by at least one cycle of CT followed
by a PN. In accordance with the French legislation, an
observational study that does not change the routine manage-
ment of patients does not need to be declared or submitted to
the opinion of a Research Ethics Board.
Although the exact indications could not be collected,
preoperative CT was performed during the study period in case
of N2 disease suspected on computed tomographic scan or for
any reason of doubtful respectability (most cases were suspi-
cions of invasion of great vessels [T4] or small but centrally
located tumors). The purpose of CT was to reduce the size of the
tumor and facilitate the surgical procedure. Mediastinoscopy
was not routinely performed, but complete ipsilateral mediasti-
nal lymphadenectomy was systematically performed.
Data Collection
During the preoperative period, the following data were
recorded: smoking habits, past and current medical comorbidi-
ties, hemoglobin and creatinine clearance after the end of induc-
tion CT, spirometric parameters, arterial blood gas values,
NSCLC characteristics (clinical tumor, node, metastasis, histol-
ogy, and side), preoperative treatment (CT type, number of
cycles and lines, toxicity, delay to surgery, RT, and response).
In the perioperative period, data collection included the
surgical procedure (route, method of suture, and method of
reinforcement of the bronchial stump), the type of PN (stan-
dard or extended), the duration of anesthesia, and the duration
of invasive-assisted ventilation.
During the postoperative period, the following data
were collected: systematic postoperative monitoring in inten-
sive care unit (ICU) (i.e., monitoring without postoperative
complication or specific preoperative risk), the major postop-
erative complications, the pathological tumor, node, metas-
tasis (pTNM) stage and the quality of the resection, the
postoperative treatment (CT and/or RT), the lung function
data, the OS, and the progression-free survival (PFS).
Statistical Analysis
The variables considered as potential prognostic factors
for at least one major postoperative complication or for
90-day mortality were first studied by univariate analysis
using 2 tests (for discrete prognostic factors) or logistic
regression (for continuous factors) (Appendix). Because
too many variables were explored, of whom some were
highly correlated, an initial multivariable model included
the classic variables already known as having a prognostic
value and found significant in the previous univariate
analysis (p  0.10). That first selection of the most repre-
sentative variables led to a model in which we tested the
prognostic impact of additional variables of interest intro-
duced stepwise. After that second selection, a final multiple
logistic regression model kept all the variables with a p value
less than 0.05 and the clinically relevant variables with a
p value between 0.05 and 0.10.
OS and PFS were calculated by the method of Kaplan-
Meier. The statistical analyses were performed with S-plus
6.0 software (Insightful).
RESULTS
Patient Characteristics
This study included 228 patients whose characteristics
are shown in Table 1. The comorbidities were chronic ob-
TABLE 1. Characteristics of the 228 Patients and Their
Disease
Characteristics Valuesa
Male 194 (85)
Age 59 (38–78)
Smoking status
Nonsmoker 15 (7)
Current smoker 102 (45)
Former smoker 99 (43)
Hemoglobinb (g/dl) 11.9 (7.7–17.0)
Creatinine clearanceb (ml/min) 73 (28–150)
Preoperative lung function
FEV1 (% predicted) 85 (47–130)
VC (% predicted) 94 (56–148)
FEV1/VC (% predicted) 72 (44–89)
TLC (% predicted) 99 (56–137)
PaO2 (kPa) 10.9 (6.3–21.2)
PaCO2 (kPa) 4.9 (3.2–7.2)
cTNM/pTNM
0 —/4 (2)
IA —/8 (4)
IB 11 (5)/28 (12)
IIA 2 (1)/6 (3)
IIB 20 (9)/51 (22)
IIIA 97 (43)/67 (29)
IIIB 71 (31)/36 (16)
IV 22 (10)/28 (12)
Unknown 5 (2)/—
Side
Right 117 (51)
Left 111 (49)
Histology
Squamous cell carcinoma 132 (58)
Adenocarcinoma 67 (29)
Large cell carcinoma 24 (11)
Other types 2 (1)
NSCLC unspecified 3 (1)
a Values are presented with the n (%) or median (min–max) form.
b After induction chemotherapy and before surgery.
FEV1, forced expiratory volume in 1 s; VC, vital capacity; TLC, total lung capacity;
NSCLC, non-small cell lung cancer; cTNM/pTNM, clinical tumor, node, metastasis/
pathological tumor, node, metastasis.
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structive pulmonary disease (COPD) in 78 patients (34%),
chronic renal failure (creatinine clearance after induction
CT 60 mL/min) in 53 (23%), arterial hypertension in 47
(21%), peripheral arterial disease in 29 (13%), another
cancer in 30 (13%), body mass index 18 or 30 in 22
(10%), diabetes mellitus in 14 (6%), phlebitis or pulmo-
nary embolism in 14 (6%), coronary disease in 11 (5%),
arrhythmia in nine (4%), and chronic heart failure in four
(2%) patients. Finally, 29 patients (13%) had three comor-
bidities or more.
A preoperative mediastinoscopy was performed in 32
patients (14%). Cases of metastasis disease before surgery
corresponded to unique metastases mostly operated before
thoracic surgery (brain or adrenal gland) or to nodules in
another lobe of the same lung. Increased number of me-
tastasis diseases after surgery is explained by unknown
nodules found in another lobe by pathologic examination
of the resected lung.
Treatment
Preoperative treatment and surgical procedures are
shown in Table 2. Induction CT types were classified into
four groups: (i) group 1 (n 164, 72%) had at least one cycle
with cisplatin and a last-generation molecule (vinorelbine,
gemcitabine, paclitaxel, and docetaxel); (ii) group 2 (n  37,
16%) had at least one cycle with cisplatin but combined only
with an “old” cytotoxic agent (mitomycin-C, ifosfamide,
vepeside, vindesine, and 5-flurouracil); (iii) group 3 (n  25,
11%) had doublets with carboplatin; and (iv) group 4 (n  2,
1%) had a monotherapy. One percent of the patients received
only one induction cycle, 25% received two cycles, 52%
received three cycles, 12% received four cycles, and 9%
received five cycles or more. Seven percent of the patients
received more than one line of CT before surgery.
Twenty-three patients (14%) received preoperative ra-
diation: thoracic radiation (n  17, dose  56 Gy [40–74
Gy]) or brain radiation (n  6). The time interval between
radiation and surgery was unknown.
A partial or a complete treatment response, based on
World Health Organization criteria, was achieved in 63% of
cases after preoperative treatment. Disease progression was
seen in 2% of cases.
Postoperative chest tube drainage was systematically
used in the four centers, its median duration was 4 days
(range, 1–11). The median posthospital stay was 11 days
(range, 2–122).
Adjuvant CT and adjuvant thoracic irradiation (mean
dose  SD: 58  8 Gy) were administered to 18% and 36%
of the patients, respectively.
Short-Term Outcomes
At least one major postoperative morbidity was noted
in 37% of the participants. Forty-one patients (18%) had at
least one major cardiac or respiratory complication: pneumo-
nia (n  17), acute respiratory failure (n  17), arrhythmia
(n  16), pericardial effusion (n  3), pulmonary embolism
(n  2), and perioperative cardiac standstill (n  1). Thirty-
nine patients (17%) had at least one major surgical compli-
cation: hemothorax (n  18), perioperative blood transfusion
of more than 2 units (n  18), bronchopleural fistula (BPF,
n  15), empyema (n  13), chylothorax (n  3), parietal
abscess (n  1), and hypertension of the cavity of PN (n 
1). Twenty-four patients (11%) had to be reoperated on for
complications: six for BPF with empyema, five for BPF
without empyema, four for hemothorax, three for empy-
ema without BPF, two for chylothorax, one for pericarditis
with tamponade, one for intestinal obstruction, one for
stroke, and one for sepsis. BPF was more frequent when
the bronchial stump was closed by hand suture only than
when a stapling device was also used (17% versus 4%).
The significant factors identified by the univariate analysis
were COPD, type of induction CT, hand suture of the
stump, extended PN, systematic postoperative monitoring
in ICU, pTNM stage IIIA, low preoperative hemoglobin,
increase length of anesthesia, and increase length of inva-
TABLE 2. Treatment Modalities
Treatment Value
Chemotherapya
Group 1
Cisplatin-vinorelbine 84 (37%)
Cisplatin-gemcitabine 67 (29%)
Cisplatin-vinorelbine-ifosfamide 9 (4%)
Others 10 (4%)
Group 2
Cisplatin-mitomycin C-ifosfamide 22 (10%)
Cisplatin-vepeside 8 (4%)
Others 7 (3%)
Group 3
Carboplatin-paclitaxel 15 (7%)
Carboplatin-gemcitabine 6 (3%)
Carboplatin-vinorelbine 7 (3%)
Group 4
Monotherapy 2 (1%)
Surgical procedure
Intrapericardial route 89 (39%)
Extended pneumonectomy 70 (31%)
Pleural resection 44 (19%)
Parietal resection 4 (2%)
Others 40 (18%)
Suture of the stump
Hand suture only 41 (18%)
Stapling device only 124 (54%)
Both 61 (27%)
Reinforcement of the stump
None 51 (22%)
Biologic paste only 85 (37%)
Pad with or without biologic paste 89 (39%)
Anesthesia
Duration (h) 2.8 (1.5–7)
Systematic postoperative monitoring in ICU 114 (50%)
Duration of postoperative monitoring in ICU (d) 1 (1–77)
Duration of postsurgical invasive ventilation (d) 0.5 (0.25–23.25)
a Total exceeds 228 because 16 patients received more than one line of induction
chemotherapy.
ICU, intensive care unit.
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sive ventilation after surgical procedure (Table 3). Factors
kept in the final multiple logistic regression model are
presented in Table 4. Type of induction CT, more than four
cycles of induction CT, extended PN, and extended anes-
thesia time were then statistically significant after multi-
variate analysis.
The mortality rates at 30 and 90 days were 5.3% (95%
confidence interval, CI: 2.7–9.0) and 9.2% (CI: 5.8–13.8),
respectively. The causes of the 21 deaths at 90 days were
acute respiratory failure unrelated to pneumonia (n  6),
pneumonia (n  6), early metastatic relapse (n  3), hem-
orrhage (n  2), empyema (n  1), acute heart failure (n 
1), stroke (n  1), and unknown (n  1). On univariate
analysis, the significant risk factors for mortality at 90 days
were COPD (16% versus 6% without COPD, p  0.03),
peripheral arterial disease (21% versus 8% without peripheral
arterial disease), and pTNM stage IIIB or IV (19% versus 6%
for pTNM stages I–IIIA). Ninety-day mortality rate was 20%
when the stump were hand sutured only versus 7% when a
stapling device were used (p  0.07). The mortality rates at
90 days in right and left PN were 10.0% and 8.2%, respec-
tively (p  0.65). On multivariate analysis, the risk factors
for mortality at 90 days were COPD, hand suture of the
stump, and pTNM stage IIIA (Table 5).
Long-Term Outcomes
The OS rates at 1, 3, and 5 years were 68%, 39%, and
32%, respectively (Figure 1). The OS rates at 5 years by
pTNM stage were 66% for stages 0 to I, 43% for stage II,
28% for stage IIIA, 11% for stage IIIB, and 8% for stage IV
TABLE 3. Significant Risk Factors for Major Morbidity
Resulting from the Univariate Analysis
Variables
Rates of Major
Morbidities (%) p
COPD 0.05
Yes 46
No 33
Type of induction CTa 0.02
Group 1 34
Group 2 56
Group 3 28
Cycles of CT 0.055
4 36
4 58
Suture of the stump 0.01
Hand sutured only 56
Stapling device only 28
Both 43
Type of pneumonectomy 0.01
Standard 31
Extended 51
Systematic postoperative monitoring
in ICU
0.0001
Yes 53
No 24
pTNM stage 0.03
I–IIIA 33
IIIB and IV 48
Low preoperative hemoglobin — 0.03
Extended anesthesia time — 0.001
Extended duration of postsurgical
invasive ventilation
— 0.007
a Group 4 was excluded from the statistical analysis because of its very low number
of patients (n  2).
COPD, chronic obstructive pulmonary disease; CT, chemotherapy; ICU, intensive
care unit; pTNM, pathological tumor, node, metastasis.
TABLE 4. Risk Factors for Major Morbidity Resulting from
the Multivariate Analysis
Variables Odds Ratio 95% CI p
COPDa
No 1.00 0.95–3.86 0.07
Yes 1.91
Type of induction CTb
Group 1 1.00 1.38–11.68 0.01
Group 2 4.02
Group 3 0.34 0.10–1.15 0.08
Cycles of CT
4 1.00 1.31–13.28 0.015
4 4.18
Type of pneumonectomya
Standard 1.00 1.74–7.80 0.001
Extended 3.68
Extended anesthesia timea 1.61 1.14–2.26 0.006
Extended duration of postsurgical
invasive ventilationa
1.01 0.94–1.09 0.79
a Variables included in the initial statistical model.
b Group 4 was excluded from the statistical analysis because of its very low number
of patients (n  2).
COPD, chronic obstructive pulmonary disease; CT, chemotherapy; CI, confidence
interval.
TABLE 5. Risk Factors for 90-d Mortality Resulting from the
Multivariate Analysis
Variables Odds Ratio 95% CI p
COPD
Yes 1.00 1.08–8.05 0.035
No 2.95
Suture of the stump
Hand sutured only 1.00 0.12–1.16 0.09
Stapling device only 0.38
Both 0.22 0.05–0.93 0.04
pTNM stage
I–IIIA 1.00 1.31–9.72 0.013
IIIB and IV 3.56
Intrapericardial route
No 1.00 0.76–5.87 0.15
Yes 2.11
Peripheral arterial disease
No 1.00 0.81–8.73 0.11
Yes 2.67
COPD, chronic obstructive pulmonary disease; CI, confidence interval.
Journal of Thoracic Oncology • Volume 4, Number 12, December 2009 Pneumonectomy After Chemotherapy in NSCLC
Copyright © 2009 by the International Association for the Study of Lung Cancer 1499
(Figure 2). Progression-free survival rates were 74% at 1
year, 42% at 3 years, and 38% at 5 years (Figure 3).
Postoperative lung function was available for a sub-
group of 138 patients. The median postoperative forced
expiratory volume in 1 second (FEV1) was 52% predicted
(range, 27–84%), the median postoperative vital capacity
(VC) was 58% predicted (range, 30–93%), and the median of
the postoperative FEV1/VC ratio was 72% predicted (range,
45–95%). At the end of the follow-up, six of the 228 patients
developed a chronic respiratory failure requiring long-time
oxygen therapy. One of these six patients required also home
mechanical ventilation.
FIGURE 1. Overall survival (Kaplan-
Meier method). One, 3, and 5-year
survivals were 68%, 39% and 32%,
respectively.
FIGURE 2. Overall 5-year survivals
by pTNM stage (Kaplan-Meier
method). Five-year survivals were 66%
for stage 0 to I, 43% for stage II, 28%
for stage IIIA, 11% for stage IIIB, and
8% for stage IV.
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DISCUSSION
To our knowledge, this work presents the largest series
assessing short- and long-term outcomes after induction CT
and PN for NSCLC. This multicenter study displayed the
outcomes of a wide array of medical and surgical practices
and, including consecutive patients, involved a wide range of
everyday thoracic oncology cases and avoided selection bias.
However, this study was limited by a retrospective
design and inclusion conditions that may have introduced
classification bias of some variables. Another limitation of
the retrospective design is that the number of patients who
could not undergo surgery because of complications of the
induction CT or disease progression was difficult to obtain.
Because pretherapeutic mediastinoscopy was not systemati-
cally performed and positron emission tomography was not
available during most of the study period, the cN stage of
some patients may have been under- or overestimated before
induction CT. No control group was available; thus, the
outcomes of our series can only be compared with those of
other published series of PN without induction CT. At least,
the analysis of the prognostic factors for 90-day mortality was
based on a limited number of patients.
In this study, we had to face a high number of potential
prognostic variables, which is a potential source of correla-
tions between some of them and a risk of false-positive
results, i.e., improper variable selection. Our three-step strat-
egy allowed testing classic variables and other clinically
relevant variables stemming from the experience of our team.
This strategy had the advantage of being entirely guided by
clinical considerations.
Despite the aforementioned caveats, our results led to
some interesting conclusions. We found a 37% rate of major
morbidity, a 30-day mortality of 5.3%, and a 90-day mortality
of 9.2% (8.0% when early metastatic relapse-related deaths
are excluded). These unfavorable outcomes are not higher
than those reported by most recent series of PN without
induction CT: morbidity rates from 39 to 47% and 30-day
mortality rates from 6.4 to 9.3%.15–18 The French recommen-
dation for the 30-day mortality rate after PN is 6% or less19;
thus, despite a rather wide 95% CI (2.7–9.0), our results are
rather encouraging. Moreover, the 5-year OSs by TNM stage
compare with those usually reported in NSCLC.20 Thus,
induction CT and PN did not adversely affect the long-term
outcomes of our patients. The OS was not obtained to the
detriment of the respiratory autonomy: only six patients
developed a chronic respiratory failure requiring long-term
oxygen therapy. For all these reasons, we believe that induc-
tion CT does not compromise short-term and long-term
outcomes after PN for NSCLC, even if PN itself remains a
major and risky procedure.
Our results suggest caution. First, COPD and pTNM
stages IIIA were found to be independent factors for mor-
tality. COPD has already been identified as a risk factor for
morbidity and mortality after PN.17,21,22 A pTNM stage
IIIA is generally considered as a poor indication for sur-
gery, especially PN, and new diagnostic techniques such as
positron emission tomography or endobronchial ultrasound
already help clinicians to properly classify patients. In our
series, many stage IV diseases were diagnosed after patho-
logic analysis of the whole lung because a nodule was found
in another lobe. In the future TNM classification, these cases
will be classified as IIIA when stage N  1.23 Thus, our
results suggest that these particular cases should still be
considered as poor indications for PN after induction CT.
Second, induction CT should be performed with platinum-
based doublets with a last-generation molecule for not more
than four cycles.6 In our study, whenever this recommenda-
tion was not followed (because it did not exist at that time),
FIGURE 3. Progression-free survival
(Kaplan-Meier method). Progression-
free survival rates were 74% at 1 year,
42% at 3 years, and 38% at 5 years.
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the postoperative morbidity was statistically higher. Third,
we have identified three independent factors for unfavorable
outcomes during the surgical procedure: extended PN and
extended anesthesia time increased postoperative morbidity
and hand suture of the bronchial stump increased postopera-
tive mortality. Extended procedures have been already re-
ported to increased morbidity16 and mortality after PN.17,21,24
PN after induction CT should be avoided whenever an ex-
tended PN seems to be inevitable before surgery (e.g., on
radiologic examination). The duration of the surgical proce-
dure in thoracic surgery should be reduced as much as
possible.25–27 This means that PN after induction CT should
be performed only by experienced surgeons.28,29 This opinion
will soon be enforced by the French authorities: a minimal
rate of thoracic procedures will be required to authorize
surgical care of NSCLC in a medical center. In agreement
with Darling et al.18 and with Patel et al.,22 our study suggests
that hand suture of the bronchial stump increases the risk of
BPF, a major complication after PN that leads to empyema,
respiratory failure, or death.18,22 In our series, a stapling
device was used in 82% of cases, which possibly explains the
low number of BPF. It is important to note that, in our series,
the method used to suture the stump depended on the sur-
geon’s experience and not, for example, on the extent of the
malignant invasion. However, the impact of hand suture of
the stump on postoperative mortality has to be considered
with caution because the study was not specifically designed
to address this question.
The reasons for the lower mortality rate in our retrospec-
tive series than in other studies are uncertain but probably linked
to several factors: clinical tumor, node, metastasis stage I or II in
15% of the patients, induction CT with platinum and a last-
generation molecule doublet in 79% of the patients, a low rate of
BPF (7%), and highly experienced centers.
However, with or without induction CT, the intrinsic
postoperative morbimortality of PN remains high. Indeed, a
9.2% of mortality rate at 90 days may still seem too heavy,
especially versus thoracic radiation in locally advanced stage
IIIA NSCLC. Comparing surgery with thoracic RT was not
the aim; however, we may note that RT is not consensual in
early-stage NSCLC and that surgery, sometimes PN, with CT
is proposed to stage II patients. In case of anatomically
appropriate early-stage NSCLC, sleeve lobectomy (SL) is an
alternative to PN. Yildizeli et al.30 reported a 30-day mortal-
ity rate of 4.1% after SL for NSCLC in a series of 218
patients (none received induction CT). Recently, a small
study showed a better postoperative quality of life after SL
than after PN.31 In a meta-analysis including almost 3000
patients, postoperative mortality and long-term survival were
lower after SL for NSCLC than after PN (OR  0.65
[0.42–1.01], p  0.05 and HR  0.70 [0.62–0.79], respec-
tively).32 These recent studies suggest that SL should be
preferred to PN when anatomically feasible, but they have
shown no results about SL after induction CT.
In conclusion, the results of this large multicenter study
seem to suggest that induction CT does not compromise
short-term and long-term outcomes after PN for NSCLC.
When performed by experienced surgeons, right or left PN
after induction CT seems to be a reasonable procedure,
especially in stage II NSCLC for which thoracic radiation
therapy is not consensual. We believe that, in stages II
NSCLC or higher, when a PN is required because of local
tumor extension, induction CT can be proposed to minimize
the size of the tumor. At the least, when SL is not technically
or anatomically possible after induction CT, then PN should
not be opposed at first.
APPENDIX
Variables analyzed to determine the risk factors for
major postoperative complications: age, sex, withdrawal of
tobacco use, quantity of tobacco used, history of ear, nose,
and throat carcinoma, COPD, diabetes mellitus, peripheral
arterial disease, coronary disease, chronic renal failure, body
mass index 18 or 30, 3 comorbidities, preoperative
hemoglobin, creatinine clearance, preoperative PaO2, preop-
erative PaCO2, VC 75 (% predicted), number of days
between the end of the induction CT and surgery, side of PN,
type of induction CT, 4 cycles of induction CT, preopera-
tive radiation, tumor response after induction treatment,
downstaging N2 after induction treatment, intrapericardial
route, type of suture of the stump, extended resection, type of
reinforcement of the bronchial stump, histology, pTNM
stage, duration of anesthesia, systematic postoperative mon-
itoring in ICU, and length of invasive ventilation after surgi-
cal procedure.
Variables analyzed to determine risk factors for 90-day
mortality: age, sex, history of COPD, peripheral arterial disease,
chronic renal failure, 3 comorbidities, preoperative hemoglo-
bin, preoperative PaO2, FEV1, VC, side of PN, type of induction
CT, 4 cycles of induction CT, preoperative radiation, intra-
pericardial route, type of suture of the stump, extended
resection, type of reinforcement of the bronchial stump,
pTNM stage, duration of anesthesia, systematic postoperative
monitoring in ICU, and length of invasive ventilation.
All effects of continuous variable were assumed linear
after checking nonlinearity using regression splines.
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